- Home
- GNK vs KROS Comparison
GNK vs KROS Comparison
Compare GNK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNK
- KROS
- Stock Information
- Founded
- GNK 2004
- KROS 2015
- Country
- GNK United States
- KROS United States
- Employees
- GNK N/A
- KROS N/A
- Industry
- GNK Marine Transportation
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- GNK Consumer Discretionary
- KROS Health Care
- Exchange
- GNK Nasdaq
- KROS Nasdaq
- Market Cap
- GNK 596.0M
- KROS 589.8M
- IPO Year
- GNK 2005
- KROS 2020
- Fundamental
- Price
- GNK $14.39
- KROS $10.86
- Analyst Decision
- GNK Strong Buy
- KROS Buy
- Analyst Count
- GNK 5
- KROS 11
- Target Price
- GNK $24.20
- KROS $45.33
- AVG Volume (30 Days)
- GNK 421.7K
- KROS 2.0M
- Earning Date
- GNK 02-19-2025
- KROS 02-26-2025
- Dividend Yield
- GNK 10.92%
- KROS N/A
- EPS Growth
- GNK 527.82
- KROS N/A
- EPS
- GNK 1.58
- KROS N/A
- Revenue
- GNK $439,330,000.00
- KROS $651,000.00
- Revenue This Year
- GNK $12.14
- KROS $303.39
- Revenue Next Year
- GNK N/A
- KROS N/A
- P/E Ratio
- GNK $9.07
- KROS N/A
- Revenue Growth
- GNK 11.14
- KROS 8037.50
- 52 Week Low
- GNK $13.51
- KROS $9.78
- 52 Week High
- GNK $23.43
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- GNK 46.22
- KROS 20.25
- Support Level
- GNK $14.21
- KROS $9.78
- Resistance Level
- GNK $14.70
- KROS $16.49
- Average True Range (ATR)
- GNK 0.38
- KROS 0.92
- MACD
- GNK 0.13
- KROS 0.97
- Stochastic Oscillator
- GNK 66.20
- KROS 14.52
About GNK Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, the ocean transportation of drybulk cargoes through the ownership and operation of drybulk carrier vessels. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.